Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
September 21, 2022
Marc CHALLANDE
BioLife Sciences (OTC: BLFE), a company that develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology, witnessed recently, on December 2021, a moment of fame when its stock price reached $2. Since then, the stock underwent a downtrend and scared plenty of investors. The company now has an incredibly meager market cap representing only $12k. Given the company’s previous increase in valuation, combined with the new products & market growth prospect, investing now in BioLife looks like a bargain.
BioLife Sciences (OTC: BLFE) aims to shape the future. Involved in disruptive technologies for the healthcare, beauty, and food & beverage sectors, the company uses cutting-edge technologies to transform everyday products into superior designs that provide consumers with safer and more effective alternatives to complete daily tasks.
One of BioLife Sciences’ avant-garde solutions is the MFusion process. Copper has been revealed to have many benefits, including inactivating various enveloped and nonenveloped viruses, such as bacteriophages, bronchitis, poliovirus, herpes simplex virus, and HIV-1. One way to achieve these benefits is to infuse copper directly into fabrics, allowing consumers a new way to take advantage of copper’s antimicrobial benefits and protections. The company offers a copper-based antimicrobial technology incorporated now into the textile fibers of clothing and other similar garments. The copper-infused garments harness the unique properties of the copper listed above, including its well-known and scientifically proven broad-spectrum antibacterial element, which kills 99.99% of bacteria within two hours of contact.
BioLife revolutionizes the copper infusion garment industry by introducing its unique copper infusion process. The company intends to launch three new products throughout 2022-2023:
-BioLife antimicrobial copper fabric pot;
-BioLife copper-infused gardening gloves;
BioLife copper-infused microfiber towels.
These products will help the company have a strong position in the gardening, farming, and agricultural communities, focusing on copper’s algaecide, fungicide, and molluscicide abilities.
On August 24, the company announced today that it would be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on disruptive hemp products. The company will focus on new and innovative product infusions centered around North American Grown, third-party tested industrial hemp geared towards providing consumers with an array of new and more effective options. BioLife will be focused on throat and cough syrups infused with cannabinoids, cannabinoid-infused teas, and CBD Energy Shots. Additionally, the company will focus on pet products infused with cannabinoids which offer wellness support for cats and dogs.
“We are so thrilled that BioLife will be focusing on this stream of business focusing on products in the marketplace which are not only disruptors but that are beneficial and useful products for consumers to seek out.”
Nika Jaksic
The US home and garden is worth $2.4B and has recently seen substantial growth during the Covid-19 pandemic, with people gardening in to spare time. The pandemic introduced a new segment of gardeners to the market, with a recent study showing that 26% of current home gardeners started gardening partly because of the COVID-19 pandemic. Due to the length of the pandemic, it is expected that 30% will continue the hobby after lockdowns and mandates have been completely removed, while an estimated 70% will abandon the practice. Based on these forecasts, BioLife will target the 30% who stick with their newfound gardening hobby as a primary focus. Many of these new gardeners are millennials who use social media networks and gardening influencers as reference points for items best suited to their needs.
Nika JAKŠIĆ (CEO) leads the company. In her past experiences, Nika JAKŠIĆ was the founder and former CEO of Health Box, which Biolife acquired in early 2022. She also spent years researching the relationship between aerobic fitness, nutritional therapy, meal planning, dietary guidance, and proper botanical supplement intake within the field of gerontology, with a focus on the loss of brain tissue in aging humans.
To increase the company’s product awareness, BioLife intends to hire new marketing operations staff while partnering with a marketing consulting firm. The company will focus on digitalization marketing with blogging, sponsor news articles, press releases, SEO ranking, and relationship building, and increase its presence through social media campaigns (via Twitter, TikTok, Facebook, Instagram, and Linkedin). According to the company, a marketing firm will assist in creating video and media presentations, podcasts, and webcasts. This plan aims to generate leads to inform the public, small businesses, and large corporations about the benefits of BioLife products and their processes. In the meantime, an investor relations firm will also be brought on to assist BioLife in corporate advising, responding to shareholder inquiries, crisis control, due diligence reporting, press release content management, social media content management, hosting virtual shareholder meetings, and conducting live and virtual quarterly earnings announcements and proxy votes.
Some of BioLife’s competitors notably include Tommie Copper, Copper 88, Copper Fit, Copper Compression, Copper Heal, and Copper Tek.
BioLife Sciences (OTC: BLFE) develops several innovative products thanks to its Mfusion process. Biolife Sciences is currently strongly undervalued, given the size of the US gardening market. The stock price is now on pause, but any important news should bring more interest and increase the company’s market cap.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts